Quest Diagnostics (DGX) has seen an array of activities and movements recently in the healthcare sector. Quest's Q4 and full year 2025 results showcased strong revenue growth, which led to a subsequent increase in their quarterly dividend by 7.5% to $0.86 per share. The company's track record leaped forward when they launched a novel flow cytometry MRD blood test for myeloma, creating an innovative pathway for ultrasensitive detection of residual disease. Their move to empower patients through an AI companion for understanding lab results is notable. Besides, Quest Diagnostics' fresh collaboration with Epic is set to improve the laboratory testing experience. Their shares have seen interesting trading patterns and were classified as a 'moderate buy' by brokerages. Additionally, Quest Diagnostics has been named in Fortune's list of World's Most Admired Companies for the 12th time consecutively. The healthcare giant has announced plans for the first quarter financial results to be released on April 21, 2026. DGX's share price, despite fluctuating, stands robust as its financial performance indicates a positive outlook for the future.
Quest Diagnostics DGX News Analytics from Tue, 15 Jul 2025 07:00:00 GMT to Fri, 27 Mar 2026 15:36:26 GMT -
Rating 6
- Innovation 9
- Information 8
- Rumor 5
